- Home
- RBNE vs RDHL Comparison
RBNE vs RDHL Comparison
Compare RBNE & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RBNE | RDHL |
|---|---|---|
| Founded | 2024 | 2009 |
| Country | Cyprus | Israel |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2M | 4.6M |
| IPO Year | N/A | 2012 |
Fundamental Metrics
Financial Performance| Metric | RBNE | RDHL |
|---|---|---|
| Price | $2.51 | $0.81 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 11.2M | 21.5K |
| Earning Date | 04-17-2026 | 11-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $381.91 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $42.51 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.67 | $0.78 |
| 52 Week High | $20.57 | $3.31 |
Technical Indicators
Market Signals| Indicator | RBNE | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 52.12 | 35.82 |
| Support Level | $1.56 | $0.80 |
| Resistance Level | $3.81 | $1.07 |
| Average True Range (ATR) | 0.37 | 0.05 |
| MACD | 0.13 | 0.00 |
| Stochastic Oscillator | 82.57 | 19.01 |
Price Performance
Historical ComparisonAbout RBNE Robin Energy Ltd.
Robin Energy Ltd operates a tanker vessel that engages in the transportation of refined petroleum products using its Handysize product tanker.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.